INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
Titel:
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
Auteur:
Hilton, John F. Ott, Patrick A. Hansen, Aaron R. Li, Zujun Mathew, Matthen Messina, Cristina H. Dave, Vimal Ji, Xiao Karpinich, Natalie O. Hirschfeld, Steven Ballas, Marc Zandberg, Dan P.